IMMPACT BIO
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
IMMPACT BIO
Social Links:
Industry:
Biotechnology Life Science
Founded:
2017-01-01
Address:
Camarillo, California, United States
Country:
United States
Website Url:
http://www.immpact-bio.com
Total Employee:
11+
Status:
Active
Total Funding:
129 M USD
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Foresite Capital
Foresite Capital investment in Series B - ImmPACT Bio
Bukwang Pharmaceutical Co
Bukwang Pharmaceutical Co investment in Series B - ImmPACT Bio
Surveyor Capital
Surveyor Capital investment in Series B - ImmPACT Bio
RM Global Partners
RM Global Partners investment in Series B - ImmPACT Bio
Decheng Capital
Decheng Capital investment in Series B - ImmPACT Bio
OrbiMed
OrbiMed investment in Series B - ImmPACT Bio
Novartis Venture Fund
Novartis Venture Fund investment in Series B - ImmPACT Bio
venBio Partners
venBio Partners investment in Series B - ImmPACT Bio
JVC Investment Partners
JVC Investment Partners investment in Series A - ImmPACT Bio
RM Global Partners
RM Global Partners investment in Series A - ImmPACT Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-09 | ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development |
| 2022-04-19 | ImmPACT Bio Names Venkat Yepuri as Chief Operating Officer |
Official Site Inspections
http://www.immpact-bio.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ImmPACT Bio"
About - ImmPACT Bio
Jonathan Benjamin is a hematologist, oncologist, and immunologist. Prior to joining ImmPACT in September 2022 as CMO, Dr. Benjamin was Senior Vice President for Clinical Research at …See details»
ImmPACT Bio - Crunchbase Company Profile & Funding
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, …See details»
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
Oct 31, 2024 Dr. Ramachandra has served as the Chief Executive Officer of ImmPACT Bio USA, Inc. since November 2021. He also served as a member of the board of directors of …See details»
ImmPACT Bio Names Jonathan Benjamin, M.D., Ph.D.
Sep 22, 2022 “On behalf of the entire ImmPACT Bio organization and board of directors, I am thrilled to welcome Jonathan as our chief medical officer,” said Sumant Ramachandra, M.D., Ph.D., M.B.A., president and CEO of ImmPACT …See details»
ImmPACT Bio Company Profile 2024: Valuation, Investors
ImmPACT Bio was founded in 2017. Where is ImmPACT Bio headquartered? ImmPACT Bio is headquartered in West Hills, CA. What is the size of ImmPACT Bio? ImmPACT Bio has 111 …See details»
Sheila Gujrathi - ImmPACT Bio
Dr. Gujrathi serves as executive chair of Ventyx Biosciences, chair of ADARx Pharmaceuticals, and director of Janux Therapeutics. She previously served as chair of Turning Point Therapeutics and is the co-founder and former CEO of …See details»
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims …
Oct 25, 2024 Lyell Immunopharma has entered a definitive agreement to acquire ImmPACT Bio, a privately-owned clinical-stage biotechnology company specialising in chimeric antigen …See details»
ImmPACT Bio Names Jonathan Benjamin, M.D., Ph.D.
Sep 13, 2022 "On behalf of the entire ImmPACT Bio organization and board of directors, I am thrilled to welcome Jonathan as our chief medical officer," said Sumant Ramachandra, M.D., Ph.D., M.B.A., president ...See details»
ImmPACT Bio Appoints Han Lee, Ph.D., MBA, as President and …
ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and …See details»
ImmPACT Bio Closes $111 Million Series B Financing, …
Jan 20, 2022 ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have exhausted their ...See details»
Novartis-backed ImmPACT Bio snags $111M and new CEO as …
Jan 20, 2022 Looking to make an impact on the cancer CAR-T cell therapy market, Novartis-backed ImmPACT Bio now has $111 million to advance its pipeline and an ex-Baxter and …See details»
ImmPACT Bio Appoints Han Lee, Ph.D., MBA, as President and …
Oct 31, 2023 ImmPACT Bio is pioneering the development of the first-and-only CD19/CD20 CAR T-cell therapy for the treatment of both B-cell driven malignancies and autoimmune …See details»
IMPT-514 Receives Investigational New Drug Clearance From the …
Aug 21, 2024 The investigational new drug application (IND) for IMPT-514 (ImmPACT Bio), a CD19/CD20 bispecific chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult …See details»
FDA OKs Phase 1 clinical trial of IMPT-514 for hard-to-treat MS
Aug 23, 2024 Immpact Bio’s IMPT-514 is a CAR T-cell therapy. In people with MS, the immune system mistakenly attacks the myelin sheath, a protective fatty coating around nerve fibers, in …See details»
ImmPACT Bio Granted FDA Fast Track Designation for IMPT-314 in …
May 15, 2023 ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients who have …See details»
ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors
Feb 8, 2023 —Seasoned executive brings decades of experience in capital markets, finance, and corporate strategy. WEST HILLS, Calif., Feb. 8, 2023 /PRNewswire/ — ImmPACT Bio …See details»
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 …
Feb 28, 2024 ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological …See details»
ImmPACT Bio Recognized in BioSpace’s 2024 Best Places to Work
Nov 8, 2023 LOS ANGELES, Calif., November 8, 2023 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen …See details»
ImmPACT Bio Doses First Patient in Phase 1/2 Trial Evaluating …
Sep 19, 2023 ImmPACT Bio's Phase 1/2 is a multi-center, open-label clinical trial that will evaluate the safety and efficacy of IMPT-314 in participants with R/R aggressive B-cell …See details»